Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 118 filers reported holding Y-MABS THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $100 | -8.3% | 18,349 | -15.6% | 0.00% | 0.0% |
| Q1 2023 | $109 | +122.4% | 21,735 | +116.1% | 0.00% | 0.0% |
| Q4 2022 | $49 | -100.0% | 10,059 | -39.2% | 0.00% | -66.7% |
| Q3 2022 | $239,000 | -13.4% | 16,542 | -9.2% | 0.00% | 0.0% |
| Q2 2022 | $276,000 | +13.6% | 18,217 | +21.3% | 0.00% | +200.0% |
| Q4 2021 | $243,000 | -67.0% | 15,020 | -41.8% | 0.00% | -66.7% |
| Q3 2021 | $737,000 | -14.3% | 25,810 | +1.5% | 0.00% | -25.0% |
| Q2 2021 | $860,000 | -2.5% | 25,436 | -12.8% | 0.00% | -20.0% |
| Q1 2021 | $882,000 | -68.6% | 29,166 | -48.6% | 0.01% | -66.7% |
| Q4 2020 | $2,808,000 | -5.6% | 56,712 | -26.8% | 0.02% | -21.1% |
| Q3 2020 | $2,975,000 | +1193.5% | 77,486 | +1355.7% | 0.02% | +850.0% |
| Q2 2020 | $230,000 | +59.7% | 5,323 | -3.8% | 0.00% | +100.0% |
| Q1 2020 | $144,000 | +35.8% | 5,533 | +63.6% | 0.00% | 0.0% |
| Q4 2019 | $106,000 | – | 3,382 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |